Search results
Showing 1141 to 1155 of 1285 results for social care
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]
Discontinued Reference number: GID-TA10212
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Discontinued Reference number: GID-TA10536
Discontinued Reference number: GID-TA10697
This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS45Show all sections
Sections for QS45
- Quality statements
- Quality statement 1: Initial assessment – physical examination
- Quality statement 2: Initial assessment – urinary frequency and volume chart
- Quality statement 3: Initial assessment – advice on lifestyle interventions
- Quality statement 4: Conservative management – temporary containment products
- Quality statement 5: Conservative management – urethral milking
- Quality statement 6: Medication review
- Quality statement 7: Specialist assessment – flow rate and post-void residual volume
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
Discontinued Reference number: GID-TA10663
Discontinued Reference number: GID-TA10429
Discontinued Reference number: GID-TA10512
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
Discontinued Reference number: GID-TA10633
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued Reference number: GID-TA10244
Discontinued Reference number: GID-TA11289
Discontinued Reference number: GID-TA10996
Evidence-based recommendations on dupilumab (Dupixent) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.